THE EFFICACY AND SAFETY OF MAGNESIUM SULPHATE FOR NEONATAL NEUROPROTECTION IN PATIENTS WITH IMMINENT PRETERM DELIVERIES: EXPERIENCE AT A TERTIARY CARE HOSPITAL
Article Sidebar
Main Article Content
Abstract
Objective
The study aimed to find the effect of 4 grams of intravenous bolus antenatal dose of magnesium Sulphate on maternal and neonatal outcomes in preterm births.
Material and Methods
In a one-year cross-sectional descriptive study, patients with active preterm labor or those with planned preterm birth at 28-34 weeks of gestation were included. Antenatal magnesium Sulphate was administered as a 4gm IV loading dose over 30 minutes. The data was analyzed with SPSS (version 20), where mean ± standard deviation was used for numerical variables and frequency and percentages for categorical variables. The sample size was 88. A P value <_0.05 is used as a threshold for statistical significance.
Results
The mean age of patients was 28.78 (± SD of 6.038) and the mean period of gestation remained 32.04 (±1.868). Similarly, the mean cervical dilatation at which magnesium Sulphate was given was 6.591 (±1.358), the mean baby’s weight was 1.655 (±0.508) kg, and the mean Apgar score at 5 minutes was recorded as 7.11 (±1.208). Regarding the period of gestation of the patients, 15 (17.04%) were at 28-30 weeks, 26 (29.54%) were at 30– 32 weeks and 47 (53.4%) were at 32– 34 weeks. Out of 88 patients, normal vaginal deliveries were conducted in 61 (69.38%) whereas, 27 (30.68%) patients had cesarean sections.
Neonatal seizures were observed in 3 (2.6%), intraventricular hemorrhage in 2 (1.754%), Periventricular leukomalacia (PVL) 1(0.877%), and neonatal mortality in 5 (4.38%).
Conclusion
Magnesium Sulphate is a safe drug that plays an important role in protecting immature brains. Four-gram bolus is a sufficient dose as compared with infusion, which requires additional human resources and risks attached to prolonged infusions.
Key Words: Magnesium Sulphate, Preterm Deliveries, Neonatal Neuroprotection, Intraventricular Hemorrhage
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.
